Go Pro

BTIG Research's Rating of Freenome on 8/17/2026

On August 17, 2026, BTIG Research updated its outlook on Freenome (NASDAQ:FRNM) with the action "Initiated Coverage", setting a "Buy" rating. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from BTIG Research

DateCompanyAction
8/17/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Reiterated Rating
8/17/2026
Apple Inc. stock logo
AAPL
Apple
Initiated Coverage
8/17/2026
ADT Inc. stock logo
ADT
ADT
Initiated Coverage
8/17/2026
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
Reiterated Rating
8/17/2026
Workday, Inc. stock logo
WDAY
Workday
Downgrade
8/14/2026
Oncobiologics, Inc. stock logo
OTLK
Oncobiologics
Reiterated Rating
More Ratings From BTIG Research